Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems

Georgianna G Gould, Marie Christine Pardon, David A Morilak, Alan Frazer

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

When patients do not respond to an initial antidepressant, one clinical approach is to switch to an agent in a different pharmacological class. However, few studies have examined the neurochemical consequences of this practice. To study this, we examined changes in binding sites in rat brain for norepinephrine (NET) and serotonin transporters (SERT), α1, α2, and β1 adrenergic receptors after chronic administration of paroxetine (PRX), reboxetine (RBX), or PRX followed by RBX. We also examined the effects of these treatments on mRNA expression for tyrosine hydroxylase (TH). RBX treatment for 3 weeks reduced NET binding significantly, by ∼40% in terminal field areas, and 6 weeks of RBX reduced it even more, by ∼60%. RBX treatment for 3 and 6 weeks reduced β1 adrenergic receptor-binding sites equally, by 50-60%. At no time did RBX treatment reduce SERT-binding sites. PRX treatment had no effect on β1 adrenergic or NET-binding sites, but reduced SERT-binding sites by 75-80%. Neither treatment altered mRNA for TH, α1, or α2 adrenergic receptor-binding sites. When 3 weeks of RBX treatment followed 3 weeks of PRX treatment, NET-binding sites were reduced to the same extent as measured after 6 weeks of RBX treatment alone, indicating that PRX pretreatment may have 'primed' the subsequent regulatory effect of RBX on the NET. Thus, pretreatment of rats with PRX actually enhanced at least one regulatory effect of RBX treatment on the noradrenergic system, and did not interfere with any other pharmacological effect caused by RBX treatment.

Original languageEnglish (US)
Pages (from-to)1633-1641
Number of pages9
JournalNeuropsychopharmacology
Volume28
Issue number9
DOIs
StatePublished - Sep 2003

Fingerprint

Paroxetine
Brain
Binding Sites
Serotonin Plasma Membrane Transport Proteins
Therapeutics
Adrenergic Receptors
Tyrosine 3-Monooxygenase
reboxetine
Pharmacology
Norepinephrine Plasma Membrane Transport Proteins
Messenger RNA
Adrenergic Agents
Antidepressive Agents

Keywords

  • Antidepressants
  • Norepinephrine transporter
  • Paroxetine
  • Quantitative autoradiography
  • Reboxetine
  • Serotonin transporter

ASJC Scopus subject areas

  • Pharmacology

Cite this

Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems. / Gould, Georgianna G; Pardon, Marie Christine; Morilak, David A; Frazer, Alan.

In: Neuropsychopharmacology, Vol. 28, No. 9, 09.2003, p. 1633-1641.

Research output: Contribution to journalArticle

@article{15ba7ebf99294fe9bce912083e368b0d,
title = "Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems",
abstract = "When patients do not respond to an initial antidepressant, one clinical approach is to switch to an agent in a different pharmacological class. However, few studies have examined the neurochemical consequences of this practice. To study this, we examined changes in binding sites in rat brain for norepinephrine (NET) and serotonin transporters (SERT), α1, α2, and β1 adrenergic receptors after chronic administration of paroxetine (PRX), reboxetine (RBX), or PRX followed by RBX. We also examined the effects of these treatments on mRNA expression for tyrosine hydroxylase (TH). RBX treatment for 3 weeks reduced NET binding significantly, by ∼40{\%} in terminal field areas, and 6 weeks of RBX reduced it even more, by ∼60{\%}. RBX treatment for 3 and 6 weeks reduced β1 adrenergic receptor-binding sites equally, by 50-60{\%}. At no time did RBX treatment reduce SERT-binding sites. PRX treatment had no effect on β1 adrenergic or NET-binding sites, but reduced SERT-binding sites by 75-80{\%}. Neither treatment altered mRNA for TH, α1, or α2 adrenergic receptor-binding sites. When 3 weeks of RBX treatment followed 3 weeks of PRX treatment, NET-binding sites were reduced to the same extent as measured after 6 weeks of RBX treatment alone, indicating that PRX pretreatment may have 'primed' the subsequent regulatory effect of RBX on the NET. Thus, pretreatment of rats with PRX actually enhanced at least one regulatory effect of RBX treatment on the noradrenergic system, and did not interfere with any other pharmacological effect caused by RBX treatment.",
keywords = "Antidepressants, Norepinephrine transporter, Paroxetine, Quantitative autoradiography, Reboxetine, Serotonin transporter",
author = "Gould, {Georgianna G} and Pardon, {Marie Christine} and Morilak, {David A} and Alan Frazer",
year = "2003",
month = "9",
doi = "10.1038/sj.npp.1300236",
language = "English (US)",
volume = "28",
pages = "1633--1641",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems

AU - Gould, Georgianna G

AU - Pardon, Marie Christine

AU - Morilak, David A

AU - Frazer, Alan

PY - 2003/9

Y1 - 2003/9

N2 - When patients do not respond to an initial antidepressant, one clinical approach is to switch to an agent in a different pharmacological class. However, few studies have examined the neurochemical consequences of this practice. To study this, we examined changes in binding sites in rat brain for norepinephrine (NET) and serotonin transporters (SERT), α1, α2, and β1 adrenergic receptors after chronic administration of paroxetine (PRX), reboxetine (RBX), or PRX followed by RBX. We also examined the effects of these treatments on mRNA expression for tyrosine hydroxylase (TH). RBX treatment for 3 weeks reduced NET binding significantly, by ∼40% in terminal field areas, and 6 weeks of RBX reduced it even more, by ∼60%. RBX treatment for 3 and 6 weeks reduced β1 adrenergic receptor-binding sites equally, by 50-60%. At no time did RBX treatment reduce SERT-binding sites. PRX treatment had no effect on β1 adrenergic or NET-binding sites, but reduced SERT-binding sites by 75-80%. Neither treatment altered mRNA for TH, α1, or α2 adrenergic receptor-binding sites. When 3 weeks of RBX treatment followed 3 weeks of PRX treatment, NET-binding sites were reduced to the same extent as measured after 6 weeks of RBX treatment alone, indicating that PRX pretreatment may have 'primed' the subsequent regulatory effect of RBX on the NET. Thus, pretreatment of rats with PRX actually enhanced at least one regulatory effect of RBX treatment on the noradrenergic system, and did not interfere with any other pharmacological effect caused by RBX treatment.

AB - When patients do not respond to an initial antidepressant, one clinical approach is to switch to an agent in a different pharmacological class. However, few studies have examined the neurochemical consequences of this practice. To study this, we examined changes in binding sites in rat brain for norepinephrine (NET) and serotonin transporters (SERT), α1, α2, and β1 adrenergic receptors after chronic administration of paroxetine (PRX), reboxetine (RBX), or PRX followed by RBX. We also examined the effects of these treatments on mRNA expression for tyrosine hydroxylase (TH). RBX treatment for 3 weeks reduced NET binding significantly, by ∼40% in terminal field areas, and 6 weeks of RBX reduced it even more, by ∼60%. RBX treatment for 3 and 6 weeks reduced β1 adrenergic receptor-binding sites equally, by 50-60%. At no time did RBX treatment reduce SERT-binding sites. PRX treatment had no effect on β1 adrenergic or NET-binding sites, but reduced SERT-binding sites by 75-80%. Neither treatment altered mRNA for TH, α1, or α2 adrenergic receptor-binding sites. When 3 weeks of RBX treatment followed 3 weeks of PRX treatment, NET-binding sites were reduced to the same extent as measured after 6 weeks of RBX treatment alone, indicating that PRX pretreatment may have 'primed' the subsequent regulatory effect of RBX on the NET. Thus, pretreatment of rats with PRX actually enhanced at least one regulatory effect of RBX treatment on the noradrenergic system, and did not interfere with any other pharmacological effect caused by RBX treatment.

KW - Antidepressants

KW - Norepinephrine transporter

KW - Paroxetine

KW - Quantitative autoradiography

KW - Reboxetine

KW - Serotonin transporter

UR - http://www.scopus.com/inward/record.url?scp=0141446183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141446183&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300236

DO - 10.1038/sj.npp.1300236

M3 - Article

VL - 28

SP - 1633

EP - 1641

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 9

ER -